Chronic Hepatitis D Infection Clinical Trial
Official title:
A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05827146 -
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
|
Phase 2 | |
| Completed |
NCT02430181 -
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
|
Phase 2 | |
| Recruiting |
NCT05765344 -
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
|
Phase 1 | |
| Recruiting |
NCT06248580 -
Find HDV and Determine Its Status in Turkey
|
||
| Recruiting |
NCT05718700 -
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
|
||
| Completed |
NCT02637999 -
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04638439 -
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
|
Phase 1 | |
| Completed |
NCT02430194 -
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
|
Phase 2 |